Drugs / GB05
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06277167 | Jan → Apr 2023 | — | Kexing Biopharm Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB05 | “GB05, human IFNα1b inhalation solution, was developed under US Food and Drug Administration (FDA) standard guidelines to combat RSV infection.” PMID 39097549 ↗ Aug 2024 |
| Known as | human IFNα1b inhalation solution | “GB05, human IFNα1b inhalation solution, was developed under US Food and Drug Administration (FDA) standard guidelines to combat RSV infection.” PMID 39097549 ↗ Aug 2024 |
| Route | Inhaled | “administered by aerosol inhalation twice a day” NCT06277167 ↗ |